The race is on. Competitive advantage rests with those who find ways to
quickly and effectively identify promising new therapeutic treatments and
diagnostic tools from enormous and complex data sets.
In recent years, scores of software vendors have produced tools for the
analysis of gene expression array data, but none has exponentially improved
the process of identifying promising genomic biomarkers. In addition, none
has produced tools that generate results consistent with the statistical
principles adopted by regulating agencies.
Using patent pending technologies developed at Fred Hutchinson Cancer
Research Center in Seattle, Enodar has developed unique approaches to
addressing the negative impact of technical and sample variations on
scientific conclusions. The result is higher quality biomarker
identification, reduced false positives, and a significant improvement in
the value of array expression. We call this approach True Discovery™.